How to Get Zetia (Ezetimibe) in Florida

Who Can Prescribe Ezetimibe in Florida

Any Florida-licensed prescriber with an active DEA registration and controlled substance license can write an ezetimibe prescription. This includes physicians (MD/DO), advanced registered nurse practitioners (ARNPs), and physician assistants (PAs). Florida Statute 464.012 grants ARNPs autonomous prescribing authority for non-controlled medications, which includes ezetimibe [2].

PAs prescribe under a supervising physician's protocol but face no additional restrictions for lipid-lowering agents. The practical distinction: ARNPs can initiate ezetimibe independently, while PAs need their supervising physician's formulary to list it. Both can prescribe via telehealth.

Board-certified cardiologists and endocrinologists most often initiate ezetimibe when statin monotherapy fails to reach LDL-C goals, though primary care providers write the majority of ongoing prescriptions. The 2018 AHA/ACC cholesterol guideline recommends adding ezetimibe when maximally tolerated statin therapy leaves LDL-C at or above 70 mg/dL in very high-risk patients [3].

Telehealth Access to Ezetimibe in Florida

Florida law permits synchronous telehealth visits (audio-video or audio-only) for establishing a prescriber-patient relationship and issuing prescriptions. No in-person visit is required first. The Florida Board of Medicine confirmed this standard under Rule 64B8-9.0141, which governs telemedicine practice standards [4].

A typical telehealth workflow looks like this: upload recent labs (lipid panel drawn within 90 days), complete a cardiovascular history intake, attend a 10- to 15-minute video consultation, and receive an electronic prescription sent directly to your chosen Florida pharmacy. Most platforms complete this cycle within 24 to 48 hours.

Several national telehealth platforms and Florida-based concierge practices prescribe ezetimibe. The prescriber reviews your statin response, confirms no contraindications (active liver disease, unexplained persistent transaminase elevations), and verifies that adding ezetimibe aligns with guideline-directed therapy. HealthRX connects Florida patients with licensed clinicians who can evaluate lipid panels and prescribe ezetimibe the same day when clinically appropriate.

Required Labs Before Starting Ezetimibe

Florida prescribers typically order two panels before initiating ezetimibe: a fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) and a hepatic function panel (AST, ALT, alkaline phosphatase, total bilirubin). The lipid panel establishes baseline LDL-C and confirms the clinical indication. The liver panel rules out active hepatic disease, since ezetimibe undergoes glucuronidation in the liver and intestinal wall [5].

The FDA label for ezetimibe states that liver function tests should be performed when co-prescribed with a statin, per the statin's labeling requirements [6]. When prescribed as monotherapy, formal hepatic monitoring is recommended at baseline but not mandated at fixed intervals.

Follow-up labs at 6 to 8 weeks post-initiation measure LDL-C response. Ezetimibe monotherapy reduces LDL-C by approximately 18% on average. Combined with a statin, the incremental reduction is 23% to 24% beyond statin-alone values, as demonstrated in the IMPROVE-IT trial population (N=18,144) where ezetimibe 10 mg plus simvastatin 40 mg achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL with simvastatin alone [1].

Insurance Coverage and Prior Authorization in Florida

Commercial insurance plans in Florida generally cover generic ezetimibe at Tier 1 or Tier 2 copay levels ($5 to $30). Brand-name Zetia lost patent exclusivity in 2016, so most formularies now list only the generic.

Florida Medicaid presents a notable exception. The Florida Agency for Health Care Administration's preferred drug list covers ezetimibe only when prescribed for patients with documented type 2 diabetes as a cardiovascular risk-reduction adjunct. Standalone hyperlipidemia without diabetes does not qualify for Florida Medicaid coverage [7]. Patients in this category face two options: appeal through the prior authorization process or pay the generic cash price (typically under $15 at discount pharmacies).

Prior authorization documentation in Florida requires:

• Diagnosis codes (ICD-10: E78.0 for pure hypercholesterolemia, E78.5 for unspecified hyperlipidemia)
• Documentation of statin trial and response (minimum 8 to 12 weeks at maximally tolerated dose)
• Most recent fasting lipid panel with LDL-C value
• Prescriber attestation that the patient meets guideline criteria for add-on therapy
• For Medicaid: confirmed T2D diagnosis (E11.x) with documented ASCVD risk

Medicare Part D plans in Florida cover ezetimibe with varying tier placement. Most assign it to Tier 2 with a $10 to $20 copay. The Medicare coverage gap (donut hole) closed for brand drugs in 2020, and generic ezetimibe rarely triggers gap-phase pricing given its low cost.

Florida Pharmacy Options and Pricing

Generic ezetimibe 10 mg is stocked at every major Florida pharmacy chain. Thirty tablets cost $8 to $12 at Costco and Walmart, $12 to $18 at CVS and Walgreens, and $15 to $25 at independent pharmacies without discount coupons. GoodRx and RxSaver consistently show sub-$15 pricing at Florida locations.

Mail-order pharmacies offer 90-day supplies for $20 to $35, which can be paired with telehealth prescriptions for maximum convenience. Express Scripts, OptumRx, and Amazon Pharmacy all ship to Florida addresses within 3 to 5 business days.

Florida-licensed 503A compounding pharmacies can prepare ezetimibe in alternative dosage forms (suspensions for dysphagia patients, combination capsules) under strict Florida Board of Pharmacy Chapter 465 oversight [8]. Compounded preparations require a patient-specific prescription and cannot be prepared in bulk for general dispensing. The Board of Pharmacy inspects 503A facilities annually and enforces USP 795 standards for non-sterile compounding.

Timeline: From Consultation to Medication in Hand

The fastest pathway delivers ezetimibe within 24 hours. Same-day telehealth appointments generate electronic prescriptions that arrive at your pharmacy within minutes. If your pharmacy stocks ezetimibe (all chains do), you can pick up the same day.

Typical timelines by access method:

• Telehealth with local pharmacy pickup: 1 to 2 days
• In-person PCP visit with local pharmacy: 1 to 3 days (appointment availability dependent)
• Telehealth with mail-order pharmacy: 4 to 7 days
• New patient with labs needed: 5 to 10 days (lab draw, results, consultation, fill)

Prescription transfers within Florida require only a pharmacist-to-pharmacist phone call or electronic transfer. Interstate transfers from another state to a Florida pharmacy are legal under Florida Statute 465.025, provided the prescription was validly issued in the originating state [9].

Transferring a Zetia Prescription to Florida

If you relocate to Florida or snowbird seasonally, transferring an existing ezetimibe prescription is straightforward. Florida accepts prescription transfers from all 50 states for non-controlled medications. Contact your new Florida pharmacy, provide your previous pharmacy's name and phone number, and the receiving pharmacist initiates the transfer.

For patients moving permanently, establishing care with a Florida-licensed provider ensures continuity. Telehealth makes this particularly efficient. Bring your most recent lipid panel results and medication list to the initial consultation. Most prescribers continue ezetimibe without interruption when prior labs confirm appropriate use.

Snowbirds maintaining dual residences can fill at Florida pharmacies using their existing out-of-state prescription, though insurance networks may require using in-network Florida pharmacies. Verify your plan's pharmacy network before transferring.

Clinical Context: Why Florida Providers Prescribe Ezetimibe

Ezetimibe inhibits the Niemann-Pick C1-Like 1 (NPC1L1) protein in the jejunal brush border, blocking intestinal cholesterol absorption by approximately 54% [5]. This mechanism complements statins, which reduce hepatic cholesterol synthesis. The combination targets two independent pathways.

The IMPROVE-IT trial enrolled 18,144 patients within 10 days of acute coronary syndrome and randomized them to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. At 7 years median follow-up, the combination reduced the primary composite endpoint (cardiovascular death, major coronary event, or nonfatal stroke) from 34.7% to 32.7%, a 6.4% relative risk reduction (HR 0.936 to 95% CI 0.89 to 0.99, P=0.016) [1].

The 2018 AHA/ACC Multi-Society Cholesterol Guideline positions ezetimibe as first-line add-on therapy after maximally tolerated statins, ahead of PCSK9 inhibitors, for patients not reaching LDL-C targets [3]. The guideline's treatment algorithm specifies: if LDL-C remains ≥70 mg/dL on high-intensity statin in very high-risk patients, add ezetimibe before considering evolocumab or alirocumab.

Florida's cardiovascular disease burden supports aggressive lipid management. The CDC reports that heart disease accounts for 21.4% of all deaths in Florida, with 47,831 cardiovascular deaths annually [10]. The state's large population over age 65 (23.4% of residents) drives high statin and ezetimibe utilization.

Ezetimibe Safety Profile and Monitoring

Ezetimibe carries a favorable side-effect profile. The most common adverse events in clinical trials were upper respiratory infection (4.3%), diarrhea (4.1%), arthralgia (3.0%), sinusitis (2.8%), and pain in extremity (2.7%), rates comparable to placebo [6].

Myalgia occurs in approximately 2% of patients on ezetimibe monotherapy. When combined with statins, myalgia rates track with the statin component rather than ezetimibe itself. The IMPROVE-IT safety data showed no increase in myopathy, rhabdomyolysis, gallbladder events, or cancer with ezetimibe over 7 years of follow-up [1].

Florida prescribers monitor hepatic transaminases if co-prescribing with a statin (per statin labeling) but do not require serial liver testing for ezetimibe monotherapy. No dose adjustment is needed for renal impairment. Patients with moderate to severe hepatic impairment (Child-Pugh score ≥7) should not use ezetimibe due to increased drug exposure [6].

Combination Therapy Options Available in Florida

Florida pharmacies stock several ezetimibe-containing combination products:

• Ezetimibe/simvastatin (generic Vytorin): 10/10, 10/20, 10/40, 10/80 mg tablets
• Ezetimibe 10 mg as standalone (generic Zetia)
• Ezetimibe plus rosuvastatin (Rhosula): FDA-approved 2023, limited early availability

The ezetimibe/simvastatin combination simplifies adherence to a single daily tablet. Generic pricing runs $15 to $40 per month in Florida. For patients requiring rosuvastatin or atorvastatin as their statin backbone, separate prescriptions for generic ezetimibe plus the generic statin remain the most cost-effective approach.

The 2022 ACC Expert Consensus Decision Pathway updated recommendations for combination lipid-lowering therapy, emphasizing that ezetimibe's low cost and established safety make it the preferred initial add-on regardless of which statin the patient takes [11].

Patients achieving less than 50% expected LDL-C reduction with ezetimibe plus maximally tolerated statin may qualify for PCSK9 inhibitor therapy. Florida commercial insurers and Medicare Part D plans require documented failure of statin plus ezetimibe combination before approving evolocumab or alirocumab.